Overview
- Lonza confirmed the Hyderabad site after an evaluation that prioritized specialized talent, quality infrastructure and a supportive industrial ecosystem.
- The centre will provide operational, digital and scientific support, including data analytics for development, regulatory documentation, digital manufacturing systems and supply-chain management.
- A Lonza delegation met Telangana Minister D. Sridhar Babu and Telangana Lifesciences CEO Shakthi M. Nagappan to formally convey the decision and discuss plans.
- Telangana officials expect substantial high-value job creation over time, with detailed timelines and headcount yet to be disclosed.
- The move aligns with a broader shift by global pharma and CDMO firms to build capability hubs in India; Lonza runs 30+ sites with about 20,000 employees and reported 2025 sales of CHF 6.5 billion.